Phenotypic/Genotypic Profile of Oxa-10-like-Harboring, Carbapenem-Resistant Pseudomonas aeruginosa: Using Validated Pharmacokinetic/Pharmacodynamic in Vivo Models to Further Evaluate Enzyme Functionality and Clinical Implications
Antimicrobial Agents and Chemotherapy
In vitro MICs and in vivo pharmacodynamics of ceftazidime and cefepime human-simulated regimens (HSR) against modified carbapenem inactivation method (mCIM)-positive Pseudomonas aeruginosa isolates harboring different OXA-10-like subtypes were described. The murine thigh model assessed ceftazidime (2 g every 8 h [q8h] HSR) and cefepime (2 g and 1 g q8h HSR). Phenotypes were similar despite possessing OXA-10-like subtypes with differing spectra. Ceftazidime produced ≥1-log10 killing in all isolates. Cefepime activity was dose dependent and MIC driven. This approach may be useful in assessing the implications of β-lactamase variants.
Print ISSN: 0066-4804; Online ISSN: 1098-6596
American Society for Microbiology
Pseudomonas aeruginosa, carbapenem resistant, cefepime, ceftazidime, in vivo, pharmacodynamics, pharmacokinetics
Tenover, Fred C.; Gill, Christian M.; Brink, Adrian; Chu, Chun Yat; Coetzee, Jennifer; Dimopoulos, George; Moodley, Clinton; Opperman, Christoffel Johannes; Pournaras, Spyros; Tickler, Isabella A.; Tootla, Hafsah Deepa; Vourli, Sophia; and Nicolau, David P., "Phenotypic/Genotypic Profile of Oxa-10-like-Harboring, Carbapenem-Resistant Pseudomonas aeruginosa: Using Validated Pharmacokinetic/Pharmacodynamic in Vivo Models to Further Evaluate Enzyme Functionality and Clinical Implications" (2021). Biology Faculty Publications. 359.